Report ID: SQMIG35I2121
Report ID:
SQMIG35I2121 |
Region:
Global |
Published Date: February, 2024
Pages:
157
|
Tables:
88 |
Figures:
81
Proteolysis-targeting chimeric molecules (PROTACs) Market size was valued at USD 125.46 Million in 2023 and is poised to grow from USD 138.26 Million in 2024 to USD 300.71 Million by 2032, growing at a CAGR of 10.20% during the forecast period (2025-2032).
PROTACs are designed to have high selectivity and specificity for their target proteins, which allows them to degrade proteins that are difficult to target using traditional small molecule inhibitors. In addition, because PROTACs induce protein degradation rather than simply inhibiting protein function, they can potentially achieve more complete and durable inhibition of target proteins.
The development of PROTACs has been driven by the need to target “undruggable” proteins, which are proteins that cannot be effectively targeted using traditional small molecule inhibitors. These undruggable proteins often lack well-defined binding pockets that can be targeted by small molecules, or they may be present in intracellular locations that are difficult for small molecules to access. By inducing protein degradation, PROTACs can effectively target these undruggable proteins by using ligands that bind to specific domains on the protein surface rather than binding to a specific binding pocket. PROTACs have been shown to be effective against a variety of protein targets, including transcription factors, kinases, and signaling proteins. One of the key advantages of PROTACs is their ability to induce protein degradation in a highly selective manner. This selectivity is achieved through the use of ligands that bind specifically to the target protein and the E3 ubiquitin ligase, which ensures that only the target protein is degraded and not other proteins in the cell.
PROTACs have also been shown to be effective in preclinical models of cancer. For example, one study demonstrated that a PROTAC targeting the androgen receptor was able to induce degradation of the receptor and inhibit the growth of prostate cancer cells in vitro and in vivo. Another study showed that a PROTAC targeting BCL-2, a protein that is overexpressed in many types of cancer, was able to induce apoptosis (programmed cell death) in cancer cells. Despite their potential as a new class of therapeutics, there are still several challenges that must be addressed in the development of PROTACs. One challenge is the design of ligands that are able to bind specifically to the target protein and the E3 ubiquitin ligase. Another challenge is the optimization of the pharmacokinetic and pharmacodynamic properties of PROTACs to ensure that they are effective and well-tolerated in vivo.
US Proteolysis-targeting chimeric molecules (PROTACs) Market is poised to grow at a sustainable CAGR for the next forecast year.
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONWant to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35I2121